TP53 and B-cell chronic lymphocytic leukemia: A 64-year-old female patient presented with unmutated IGVH (UM-CLL), TP53 mutation, and refractory disease after sequential treatment with FCR (fludarabine, cyclophosphamide, rituximab), FC, and ibrutinib (Fig. 3a).